Karl Hsu

1.8k total citations
24 papers, 1.2k citations indexed

About

Karl Hsu is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Karl Hsu has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 11 papers in Cell Biology and 7 papers in Oncology. Recurrent topics in Karl Hsu's work include Zebrafish Biomedical Research Applications (7 papers), Multiple Myeloma Research and Treatments (4 papers) and Microtubule and mitosis dynamics (4 papers). Karl Hsu is often cited by papers focused on Zebrafish Biomedical Research Applications (7 papers), Multiple Myeloma Research and Treatments (4 papers) and Microtubule and mitosis dynamics (4 papers). Karl Hsu collaborates with scholars based in United States, France and Cameroon. Karl Hsu's co-authors include John P. Kanki, A. Thomas Look, Jennifer Rhodes, Ting Xi Liu, Richard J Maraia, Min Deng, David M. Langenau, Dau‐Yin Chang, Jason N. Berman and Éric Charpentier and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Karl Hsu

24 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karl Hsu United States 17 763 485 298 243 178 24 1.2k
K Letwin Canada 11 1.0k 1.3× 292 0.6× 250 0.8× 94 0.4× 222 1.2× 12 1.4k
Jessica S. Blackburn United States 19 793 1.0× 521 1.1× 212 0.7× 165 0.7× 264 1.5× 53 1.4k
Daniela Talarico Italy 18 811 1.1× 232 0.5× 177 0.6× 134 0.6× 135 0.8× 41 1.2k
Patrick Rodriguez Netherlands 11 969 1.3× 207 0.4× 115 0.4× 180 0.7× 90 0.5× 13 1.2k
Samuel D. Foster United Kingdom 8 980 1.3× 263 0.5× 218 0.7× 407 1.7× 157 0.9× 8 1.4k
A MacAuley United States 14 1.1k 1.4× 336 0.7× 285 1.0× 66 0.3× 327 1.8× 19 1.6k
Jennifer L. Shepard United States 7 735 1.0× 588 1.2× 209 0.7× 90 0.4× 111 0.6× 7 1.1k
Cicely A. Jette United States 18 884 1.2× 518 1.1× 206 0.7× 71 0.3× 188 1.1× 25 1.2k
Areum Han United States 17 1.1k 1.4× 236 0.5× 176 0.6× 149 0.6× 140 0.8× 31 1.5k
Susheela Dhut United Kingdom 18 1.3k 1.7× 413 0.9× 92 0.3× 231 1.0× 184 1.0× 31 1.6k

Countries citing papers authored by Karl Hsu

Since Specialization
Citations

This map shows the geographic impact of Karl Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Hsu more than expected).

Fields of papers citing papers by Karl Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Hsu. The network helps show where Karl Hsu may publish in the future.

Co-authorship network of co-authors of Karl Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Hsu. A scholar is included among the top collaborators of Karl Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Hsu. Karl Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martin, Thomas G., Stephen A. Strickland, Martha Glenn, et al.. (2019). Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer Journal. 9(4). 41–41. 70 indexed citations
2.
Bechter, Oliver, Herlinde Dumez, Kevin Punie, et al.. (2016). Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma. Cancer Chemotherapy and Pharmacology. 78(1). 83–90. 4 indexed citations
3.
Martin, Thomas G., Joshua Richter, Ravi Vij, et al.. (2015). A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. Blood. 126(23). 509–509. 26 indexed citations
4.
Heist, Rebecca S., Leena Gandhi, Geoffrey I. Shapiro, et al.. (2013). Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.. Journal of Clinical Oncology. 31(15_suppl). 2530–2530. 20 indexed citations
5.
Infante, Jeffrey R., Geoffrey I. Shapiro, Naiyer A. Rizvi, et al.. (2013). Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.. Cancer Research. 73(8_Supplement). LB–147. 16 indexed citations
6.
Holen, Kyle D., Robert S. DiPaola, Glenn Liu, et al.. (2011). A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors. Investigational New Drugs. 30(3). 1088–1095. 50 indexed citations
7.
Liu, Ting Xi, Jennifer Rhodes, Min Deng, et al.. (2007). Dominant-interfering C/EBPα stimulates primitive erythropoiesis in zebrafish. Experimental Hematology. 35(2). 230–239. 21 indexed citations
8.
Stein, Mark N., Alan Tan, Katherine Johansen Taber, et al.. (2007). Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2548–2548. 4 indexed citations
9.
Rhodes, Jennifer, Karl Hsu, Min Deng, et al.. (2005). Interplay of Pu.1 and Gata1 Determines Myelo-Erythroid Progenitor Cell Fate in Zebrafish. Developmental Cell. 8(1). 97–108. 292 indexed citations
10.
Berghmans, Stéphane, Cicely A. Jette, David M. Langenau, et al.. (2005). Making Waves in Cancer Research: New Models in the Zebrafish. BioTechniques. 39(2). 227–237. 127 indexed citations
11.
Hsu, Karl, A. Thomas Look, & John P. Kanki. (2004). Lessons from Transgenic Zebrafish Expressing the Green Fluorescent Protein (GFP) in the Myeloid Lineage. Methods in cell biology. 77. 333–347. 2 indexed citations
12.
Hsu, Karl, David Traver, Jeffery L. Kutok, et al.. (2004). The pu.1 promoter drives myeloid gene expression in zebrafish. Blood. 104(5). 1291–1297. 121 indexed citations
13.
Liu, Ting Xi, Niall G. Howlett, Min Deng, et al.. (2003). Knockdown of Zebrafish Fancd2 Causes Developmental Abnormalities via p53-Dependent Apoptosis. Developmental Cell. 5(6). 903–914. 89 indexed citations
14.
Berman, Jason N., Karl Hsu, & A. Thomas Look. (2003). Zebrafish as a model organism for blood diseases. British Journal of Haematology. 123(4). 568–576. 41 indexed citations
15.
Hsu, Karl, John P. Kanki, & A. Thomas Look. (2001). Zebrafish myelopoiesis and blood cell development. Current Opinion in Hematology. 8(4). 245–251. 27 indexed citations
16.
Hsu, Karl, Dau‐Yin Chang, & Richard J Maraia. (1995). Human Signal Recognition Particle (SRP) Alu-associated Protein Also Binds Alu Interspersed Repeat Sequence RNAs. Journal of Biological Chemistry. 270(17). 10179–10186. 48 indexed citations
17.
Chang, Dau‐Yin, et al.. (1994). A Human Alu RNA-Binding Protein Whose Expression Is Associated with Accumulation of Small Cytoplasmic Alu RNA. Molecular and Cellular Biology. 14(6). 3949–3959. 15 indexed citations
18.
Chang, Daniel, et al.. (1994). A human Alu RNA-binding protein whose expression is associated with accumulation of small cytoplasmic Alu RNA.. Molecular and Cellular Biology. 14(6). 3949–3959. 33 indexed citations
19.
Maraia, Richard J, et al.. (1993). Multiple dispersed loci produce small cytoplasmic Alu RNA.. Molecular and Cellular Biology. 13(7). 4233–4241. 68 indexed citations
20.
Maraia, Richard J, Dau‐Yin Chang, Alan P. Wolffe, Roseann L. Vorce, & Karl Hsu. (1992). The RNA Polymerase III Terminator Used by a B1- Alu Element Can Modulate 3′ Processing of the Intermediate RNA Product. Molecular and Cellular Biology. 12(4). 1500–1506. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K Letwin Breakdown of academic impact, for papers by Jessica S. Blackburn Breakdown of academic impact, for papers by Daniela Talarico Breakdown of academic impact, for papers by Patrick Rodriguez Breakdown of academic impact, for papers by Samuel D. Foster Breakdown of academic impact, for papers by A MacAuley Breakdown of academic impact, for papers by Jennifer L. Shepard Breakdown of academic impact, for papers by Cicely A. Jette Breakdown of academic impact, for papers by Areum Han Breakdown of academic impact, for papers by Susheela Dhut
Rankless by CCL
2026